Author:
Hu Xuekai,Wei Jiayun,Liu Pinyan,Zheng Qiuxia,Zhang Yue,Zhang Qichen,Yao Jia,Ni Jingman
Abstract
AbstractPrimary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine.
Funder
National Natural Science Foundation of China
Talent Innovation and Entrepreneurship Project in Chengguan District, Lanzhou City, Gansu Province
First Clinical Medical School, Lanzhou University
Publisher
Springer Science and Business Media LLC